NeuroOne Reports Q2 2025 Financial Results with Increased Revenue and Reduced Net Loss

NeuroOne Medical Technologies Corporation reported its financial results for the second quarter of fiscal year 2025, revealing a product revenue of $1.39 million for the three months ended March 31, 2025, a slight increase from $1.38 million in the same period last year. For the six months ending March 31, 2025, the company generated $4.66 million in product revenue, significantly up from $2.35 million during the same period in 2024. The gross profit for the latest quarter was $771,061, representing a gross margin of 55.6%, compared to 28.3% in the prior year, attributed to higher-margin OneRF products being sold.

The company’s net loss for the three months ended March 31, 2025, was $2.27 million, an improvement from a loss of $2.86 million in the same quarter of 2024. For the six-month period, the net loss narrowed to $485,285 from $6.20 million year-over-year. The reduction in losses is partly due to a decrease in operating expenses, which totaled $3.45 million for the latest quarter, down from $3.28 million in the previous year. The company also reported a fair value change in warrant liability of $390,351, contributing to the improved financial performance.

Strategically, NeuroOne has made significant advancements, including an amended distribution agreement with Zimmer, Inc., which grants Zimmer exclusive rights to distribute the OneRF Ablation System. This agreement included an upfront payment of $3 million and potential additional payments based on sales milestones. The company also filed a 510(k) submission with the FDA for its OneRF Trigeminal Nerve Ablation System, expanding its product offerings in the neuromodulation market.

Operationally, NeuroOne's total assets decreased to $4.46 million as of March 31, 2025, down from $5.37 million at the end of the previous fiscal year. The company reported a cash balance of $1.32 million, which is expected to be bolstered by approximately $8.2 million in net proceeds from a recent financing round completed in April 2025. The company anticipates that this capital, along with projected increases in product revenues, will be sufficient to fund its operations for at least the next twelve months.

Looking ahead, NeuroOne remains focused on expanding its product lines and increasing market share in the neuromodulation sector. The company acknowledges the ongoing challenges posed by global economic conditions, including inflation and supply chain disruptions, but is optimistic about its growth trajectory, particularly with the anticipated revenue from its collaboration with Zimmer and the commercialization of its new products.